Corteva, Inc. (CTVA)
NYSE: CTVA · Real-Time Price · USD
79.42
-0.38 (-0.48%)
At close: Apr 27, 2026, 4:00 PM EDT
79.44
+0.02 (0.03%)
After-hours: Apr 27, 2026, 4:00 PM EDT

Corteva Earnings Call Transcripts

Fiscal Year 2026

Fiscal Year 2025

  • Delivered strong 2025 results with double-digit EBITDA growth, margin expansion, and robust free cash flow. 2026 guidance calls for 7% EBITDA growth, margin gains, and accelerated royalty neutrality following a major Bayer agreement, despite ongoing pricing and tariff headwinds.

  • Strong Q3 and year-to-date results led to raised 2025 guidance, with double-digit EBITDA growth, margin expansion, and robust free cash flow. The planned separation into two public companies is on track, with both seed and crop protection segments showing innovation and market leadership.

  • Investor Update

    A separation into two companies—crop protection and seed—was announced to unlock long-term value, with both entities retaining strong balance sheets and tailored growth strategies. The split is expected to be low in complexity, with manageable costs and no new liabilities anticipated.

  • Q2 and H1 2025 saw strong sales, margin expansion, and cost improvements, leading to raised full-year guidance for EBITDA, EPS, and free cash flow. Seed and crop protection segments both delivered double-digit EBITDA growth, with robust share gains and new product momentum.

  • Strategy and execution improvements have driven strong financial performance and optimism, with technology and product innovation setting up for significant growth. Tariff impacts are manageable, cost efficiencies are on track, and new products like hybrid wheat and short-stature corn are expected to launch in 2027. Capital allocation remains balanced, supporting both shareholder returns and R&D.

  • Q1 delivered 15% EBITDA growth, driven by new products, cost improvements, and strong volumes, with full-year guidance up 10%. Innovation in gene editing, hybrid wheat, and biologicals underpins a robust pipeline, while tariff and FX headwinds are being actively managed.

  • Q1 2025 saw 15% EBITDA growth and nearly 400 bps margin expansion, driven by operational excellence and growth in biologicals, new crop protection products, and seed out-licensing. Full-year guidance is reaffirmed, with manageable tariff impacts and strong cost savings supporting robust outlook.

  • Entering 2025 with strong global demand, tight crop inventories, and healthy pricing, the company projects double-digit EBITDA and EPS growth, driven by proprietary products, out-licensing, and biologicals. Strategic M&A, cost discipline, and innovation in gene editing and biofuels underpin long-term growth.

Fiscal Year 2024

Fiscal Year 2023

Fiscal Year 2022

Fiscal Year 2021

Fiscal Year 2020

Fiscal Year 2019

Powered by